Engineered Exosomes-Mediated Transfer of hsa-miR-320a Overcomes Chemoresistance in Cervical Cancer Cells via Targeting MCL1

Jinling Zhou; Yuanhe Wang; Lizhu Zhang; Qin Chen; Xiaojun Zhu; Peiyue Jiang; Nan Jiang; Wei Zhao; Baohua Li

doi:10.3389/fphar.2022.883445

Engineered Exosomes-Mediated Transfer of hsa-miR-320a Overcomes Chemoresistance in Cervical Cancer Cells via Targeting MCL1

Front Pharmacol. 2022 Apr 4:13:883445. doi: 10.3389/fphar.2022.883445. eCollection 2022.

Authors

Jinling Zhou¹, Yuanhe Wang¹, Lizhu Zhang², Qin Chen³, Xiaojun Zhu¹, Peiyue Jiang¹, Nan Jiang⁴, Wei Zhao⁵, Baohua Li¹

Affiliations

¹ Department of Obstetrics and Gynecology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
² Institute of Nanjing Nanxin Pharmaceutical Technology Research, Nanjing, China.
³ Department of Pathology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
⁴ Department of Clinical Laboratory, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, China.
⁵ Department of Biomedical Sciences and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong, Hong Kong SAR, China.

Abstract

In cervical cancer (CC), cisplatin resistance greatly restricts the application in clinical. Here, we report that engineered exosomes-mediated transfer of hsa-miR-320a overcomes chemoresistance in cervical cancer cells via targeting Myeloid Cell Leukemia Sequence 1 (MCL1). In DDP resistant CC tissues, as well as cell lines, it was found that miR-320a expression is lower, engineered miR-320a exosomes were used to attenuate DDP resistance in Hela/DDP and Caski/DDP cells. Mechanistically, we find that MCL1, which is a target of miR-320a, overcomes DDP resistance in Hela/DDP cells and in mice. In conclusion, we report that the engineered miR-320a exosomes is proved to be effective and safe.

Keywords: Mcl1; cervical cancer; chemoresistance; engineered exosomes; has-miR-320a.